| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2771927 | Seminars in Arthritis and Rheumatism | 2007 | 5 Pages |
Abstract
The present analysis identified pulmonary fibrosis and Raynaud's phenomenon preceding SSc skin manifestations by at least 3 years as risk factors for PAH in our scleroderma cohort. Screening for PAH in these high-risk patients may detect PAH at an earlier stage and guide decisions on therapeutic interventions.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Sotiris C. MD, Stylianos P. MD, Christos MD, Haralampos M. MD, FACP, FRCP, George E. MD,